10.6084/m9.figshare.4519811.v2
Xue C.
Xue
C.
Yang B.
Yang
B.
Zhou C.
Zhou
C.
Dai B.
Dai
B.
Liu Y.
Liu
Y.
Mao Z.
Mao
Z.
Yu S.
Yu
S.
Mei C.
Mei
C.
PowerPoint Slides for: Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease
Karger Publishers
2017
Chronic kidney disease
Fibroblast growth factor 23
All-cause mortality
Cardiovascular diseases
End-stage renal disease
Meta-analysis
2017-01-11 10:12:01
Presentation
https://karger.figshare.com/articles/presentation/PowerPoint_Slides_for_Fibroblast_Growth_Factor_23_Predicts_All-Cause_Mortality_in_a_Dose-Response_Fashion_in_Pre-Dialysis_Patients_with_Chronic_Kidney_Disease/4519811
<p><b><i>Background:</i></b> Quantitative dose-response associations
between fibroblast growth factor 23 (FGF23) and risks of mortality,
cardiovascular disease (CVD), and renal events in chronic kidney disease
(CKD) are not known. This study aimed to summarize and quantify the
predictive effects of FGF23 among the pre-dialysis CKD stages 1-5
population. <b><i>Methods:</i></b> Data sources included PubMed, EMBASE,
and Web of Science. Prospective cohort studies assessing the
associations between FGF23 and all-cause mortality, CVD, and renal
events in CKD patients were selected. Summary risk ratios (RRs) and 95%
confidence intervals (CIs) were calculated using the random-effects
model. The composite higher or the highest level in FGF23 categories of
each study was considered the high level. The reference level was
regarded as the low level in the overall analysis. The restricted cubic
spline model was used to estimate dose-response associations. <b><i>Results:</i></b>
Fifteen prospective cohort studies centered around 15,355 subjects were
analyzed. A high FGF23 level was associated with increased risks of
all-cause mortality (RR 1.46, 95% CI 1.38-1.55, <i>p</i> < 0.001), CVD (RR 1.37, 95% CI 1.15-1.63, <i>p</i> < 0.001), and renal events (RR 1.31, 95% CI 1.07-1.59, <i>p </i>=
0.008), respectively. There was a positive, nonlinear, dose-response
relationship between FGF23 and all-cause mortality. The reference level
in dose-response analysis was defined as 51 RU/mL of c-terminal FGF23.
We then calculated RRs for increments of 20 RU/mL, which was associated
with increased risks of mortality (RR 1.04, 95% CI 1.00-1.07, <i>p</i> = 0.038), CVD (RR 1.02, <i>p</i> < 0.001), and renal events (RR 1.01, <i>p</i> < 0.001), respectively. <b><i>Conclusions:</i></b>
There may be positive dose-response predictive effects of FGF23 on
all-cause mortality, CVD, and renal events in patients with CKD.</p>